A “LIVE” globally-broadcasted, Internet-only “virtual” video satellite symposium at 4:30PM (Eastern Time USA) on May 31, 2020 during the annual ASCO meeting.
TITLE: Optimizing Outcome in ALK-Positive Non-Small Cell Lung Cancer: Using Precision Medicine & Patient Assessments for Personalized First-Line ALK-Targeted Therapy
This live virtual symposium will help academic & community-based oncologists, pulmonologists, pathologists, pharmacists, nurses, NPs & PAs with the diagnosis of NSCLC in patients with ALK-gene fusion rearrangements, and, subsequently with the development of optimal first-line treatment plans.
The presentations and panel discussions by the expert faculty will address key challenges facing clinicians treating newly-diagnosed ALK-positive NSCLC patients. The symposium will help clinicians integrate several current and emerging critical decision-making factors to be used for devising initial ALK TKI therapy, including systemic & CNS TKI efficacy, resistance mechanisms to ALK TKIs, molecular diagnostic testing for the ALK-gene fusion rearrangements, and methodologies for assessing patients’ needs & lifestyles, and the overall tolerability with daily, chronic ALK TKI therapy. These critical decision-making factors will help clinicians improve patient outcomes with optimal, personalized, first-line treatment plans in ALK-positive NSCLC.
Faculty members will ask questions of the participants. Questions will be treatment-related and derived from the clinical case studies. The participants can submit questions to the faculty and up vote their questions at any time. And although virtual, it provides the same ability for extensive interaction between the participants and faculty as can be achieved with any in-person symposium.